Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model

International Immunopharmacology

Volumn 10, Issue 4, 2010, Pages 533-539

  Hsu, Chuan Long ^a   Shiung, Yu Yu ^a   Lin, Bai Ling ^b   Chang, Hwan You ^a   Chang, Tse Wen ^b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Allergen trapping; Allergy; Anti IgE; Basophils; In vitro reconstitution; Omalizumab

Indexed keywords

ALLERGEN; ANTIGEN; IMMUNOGLOBULIN E; OMALIZUMAB; OVALBUMIN;

ANIMAL CELL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BASOPHIL; BINDING AFFINITY; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; GENETIC TRANSFECTION; IN VITRO STUDY; MAST CELL; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALLERGENS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; BASOPHILS; BETA-N-ACETYLHEXOSAMINIDASES; BLOTTING, WESTERN; CELL LINE; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FC FRAGMENTS; RATS; STAPHYLOCOCCAL PROTEIN A;

EID: 77949654721     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.02.001     Document Type: Article

References (34)

1. Chang T.W. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 18 (2000) 157-162
2. Lanier B.Q. Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE. Ann Allergy Asthma Immunol 90 (2003) 13-15
3. Holgate S.T., Djukanovic R., Casale T., and Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 35 (2005) 408-416
4. Berger W.E. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody. Allergy Asthma Proc 27 (2006) S29-S32
5. Chang T.W., Wu P.C., Hsu C.L., and Hung A.F. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol 93 (2007) 63-119
6. Corren J., Casale T.B., Lanier B., Buhl R., Holgate S., and Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 39 (2009) 788-797
7. Chang T.W., and Shiung Y.Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 117 (2006) 1203-1212 quiz 13
8. MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 114 (2004) 1472-1474
9. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol 114 (2004) 527-530
10. Lin H., Boesel K.M., Griffith D.T., Prussin C., Foster B., Romero F.A., et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 113 (2004) 297-302
11. Belloni B., Ziai M., Lim A., Lemercier B., Sbornik M., Weidinger S., et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120 (2007) 1223-1225
12. Forman S.B., and Garrett A.B. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis 80 (2007) 38-40
13. Lane J.E., Cheyney J.M., Lane T.N., Kent D.E., and Cohen D.J. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54 (2006) 68-72
14. Lim A., Luderschmidt S., Weidinger A., Schnopp C., Ring J., Hein R., et al. The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without variable region of the heavy immunoglobulin chain bias. J Allergy Clin Immunol 120 (2007) 696-706
15. Sheinkopf L.E., Rafi A.W., Do L.T., Katz R.M., and Klaustermeyer W.B. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29 (2008) 530-537
16. Spector S.L., and Tan R.A. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 99 (2007) 190-193
17. van der Ent C.K., Hoekstra H., and Rijkers G.T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62 (2007) 276-277
18. Hayashi N., Tsukamoto Y., Sallas W.M., and Lowe P.J. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63 (2007) 548-561
19. Liu J., Lester P., Builder S., and Shire S.J. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34 (1995) 10474-10482
20. Fox J.A., Hotaling T.E., Struble C., Ruppel J., Bates D.J., and Schoenhoff M.B. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 279 (1996) 1000-1008
21. Demeule B., Shire S.J., and Liu J. A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation. Anal Biochem 388 (2009) 279-287
22. Casale T.B., Bernstein I.L., Busse W.W., LaForce C.F., Tinkelman D.G., Stoltz R.R., et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100 (1997) 110-121
23. Milgrom H., Fick Jr. R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341 (1999) 1966-1973
24. Dibbern Jr. D.A., Palmer G.W., Williams P.B., Bock S.A., and Dreskin S.C. RBL cells expressing human Fc epsilon RI are a sensitive tool for exploring functional IgE-allergen interactions: studies with sera from peanut-sensitive patients. J Immunol Methods 274 (2003) 37-45
25. Sun L.K., Liou R.S., Sun N.C., Gossett L.A., Sun C., Davis F.M., et al. Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity. J Immunol 146 (1991) 199-205
26. Feuchtinger T., Bartz H., von Berg A., Riedinger F., Brauburger J., Stenglein S., et al. Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season. J Allergy Clin Immunol 111 (2003) 428-430
27. Ladics G.S., van Bilsen J.H., Brouwer H.M., Vogel L., Vieths S., and Knippels L.M. Assessment of three human FcepsilonRI-transfected RBL cell-lines for identifying IgE induced degranulation utilizing peanut-allergic patient sera and peanut protein extract. Regul Toxicol Pharmacol 51 (2008) 288-294
28. Corren J., Fish H., and Gumarange J. Nasal response to natural cat allergen exposure is significantly greater in patients with rhinitis and asthma than in patients with rhinitis alone. J Allergy Clin Immunol 115 (2005) 202-203
29. Mosimann B., Aubert V., Frey J.G., Leuenberger P., and Pecoud A. Bronchial provocation with cat allergen: correlation between the individual IgE-CRIE pattern and the occurrence of a late allergic reaction. Clin Exp Allergy 24 (1994) 46-52
30. Emmett S.E., Angus F.J., Fry J.S., and Lee P.N. Perceived prevalence of peanut allergy in Great Britain and its association with other atopic conditions and with peanut allergy in other household members. Allergy 54 (1999) 380-385
31. Leung D.Y., Sampson H.A., Yunginger J.W., Burks Jr. A.W., Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348 (2003) 986-993
32. Moneret-Vautrin D.A., Rance F., Kanny G., Olsewski A., Gueant J.L., Dutau G., et al. Food allergy to peanuts in France-evaluation of 142 observations. Clin Exp Allergy 28 (1998) 1113-1119
33. van der Heijden F.L., Joost van Neerven R.J., van Katwijk M., Bos J.D., and Kapsenberg M.L. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 150 (1993) 3643-3650
34. van Neerven R.J., Arvidsson M., Ipsen H., Sparholt S.H., Rak S., and Wurtzen P.A. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 34 (2004) 420-428